Clinical utility of serum chemerin as a novel marker of metabolic syndrome and type 2 diabetes mellitus

Life Science Journal

Volumn 9, Issue 2, 2012, Pages 1098-1108

  Osman, Mona M ^a   El mageed, Abeer I Abd ^a   El hadidi, Eman ^a   Shahin, Rania S K ^a   Mageed, Nanees A A Adel ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Chemerin; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

EID: 84872967401     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. American Heart Association/ National Heart, Lung, and Blood Institute Conference on Scientific Issues Related to Definition (2004): Definition of Metabolic Syndrome. Circulation; 109: 433-438.
2. Assman G.; Schriewer H.; Schmitz G. and Hagele E. O. (1983): Quantification of high density lipoprotein cholesterol by precipitation with phosphotungestic acid/MgC12. Clin. Chem.; 29: 2026-2027.
3. Blüher M, Rudich A, Klöting N, Golan R, Henkin Y, Rubin E, Schwarzfuchs D, Gepner Y, Stampfer MJ, Fiedler M, Thiery J, Stumvoll M and Shai I. (2012): Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care; 35 (2): 342-9.
4. Bozaoglu K.; Bolton K.; McMillan J.; Zimmet P.; Jowett J.; Collier G.; Walder K. and Segal D. (2007): Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology; 148: 4687-4694.
5. Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N, Morrison S, Carless M, Dyer TD, Cole SA, Goring HH, Moses EK and Walder K, (2010): Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab; 95 (5): 2476-85.
6. Bozaoglu K.; Segal D., Shields K., Cummings, N., Curran, J, Comuzzie, A., Mahaney, M., Rainwater, D., VandeBerg, J., MacCluer, J., Collier, G. and Jowett, J. (2009): Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population, The Journal of Clinical Endocrinology & Metabolism; 94 (8): 3085-3088.
7. Carl A.; Ashwood E. R. and Bruns D. E. (2006): Lipids, lipoproteins, apolipoproteins and other cardiovascular risk factors. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics; 2: 903-967.
8. Chakaroun R, Raschpichler M, Klöting N, Oberbach A, Flehmig G, Kern M, Schön MR, Shang E, Lohmann T, Dreßler M and Fasshauer M, (2011): Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism; 61 (5) 706-714.
9. Dietschy J. M.; Weeks L. E. and Delento J. J. (1976): Enzymatic assessment of free and estrified cholesterol levels using the oxygen electrode in a modified glucose analyzer. Clin. Chem. Acta; 73: 407.
10. Dong B, Ji W and Zhang Y (2011): Elevated Serum Chemerin Levels are Associated with the Presence of Coronary Artery Disease in Patients with Metabolic Syndrome. Intern Med.; 50 (10): 1093-7.
11. El-Mesallamy HO, El-Derany MO and Hamdy NM. (2011): Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med.; 28 (10): 1194-200.
12. Ernst M. C, Haidl I. D, Zúñiga L. A, Dranse H. J, Rourke J. L, Zabel BA, Butcher E. C, Sinal CJ. (2012): Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology; 153 (2): 672-82.
13. Ernst M. C.; Issa M.; Goralski K. B. and Sinal C. J. (2010): Chemerin Exacerbates Glucose Intolerance in Mouse Models of Obesity and Diabetes. Endocrinology; 151 (5): 1998-2007.
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997): Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care; 20: 1183.
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003): Followup report on the diagnosis of diabetes mellitus. Diabetes Care; 26: 3160.
16. Ferraccioli G and Gremese E. (2011): Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Med Wkly. 27; 141.
17. Friedwald W. T.; Levy R. I. and Fridrickson D. S. (1972): Estimation of the concentration of lowdenisty lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin. Chem.; 18: 449-501.
18. Hart, R. and Greaves, D. R. (2010): Chemerin Contributes to Inflammation by Promoting Macrophage Adhesion to VCAM-1 and Fibronectin through Clustering of VLA-4 and VLA-5Journal of Immunology; 185: (6) 3728-3739.
19. Hu W and Feng P. (2011): Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract.; 91 (2): 159-63.
20. Iannone F and Lapadula G. (2011): Chemerin/ChemR23 pathway: a system beyond chemokines. Arthritis Res Ther.; 13 (2): 104.
21. James J. C. l, Nancy, S., and Arthur L. B. (1970): A colorimetric serum glucose determination using hexokinase and glucose-6-phosphate dehydrogenase. Biochemical Medicine; 4 (2): 171-180.
22. Jennifer C. R., Jennifer C. L. and Richard T. T. (1999): Comparison of a Radioimmunoassay with a Microparticle Enzyme Immunoassay of Insulin for Use with the Minimal Model Method of Determining Whole-Body Insulin Sensitivity. Diabetes Technology & Therapeutics; 1 (4): 463-468.
23. Lambernd S, Taube A, Schober A, Platzbecker B, Görgens SW, Schlich R, Jeruschke K, Weiss J, Eckardt K, Eckel J. (2012): Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. Diabetologia.; 55 (4): 1128-39.
24. Lehrke M.; Becker A.; Greif M.; Stark R.; Laubender RP.; von Ziegler F.; Lebherz C.; Tittus J.; Reiser M.; Becker C.; Göke B.; and Broedl U. C. (2009): Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol; 161 (2): 339-344.
25. Lin C. C.; Liu C. S.; Li C. I.; Lin W. Y.; Lai M. M.; Lin T.; Chang P. C.; Lee Y. D.; Chen C. C.; Lin C. H.; Yang C. W.; Hsiao C. Y; Chen W. and Li T. C. (2009): The relation of metabolic syndrome according to five definitions to cardiovascular risk factors-a population-based study. B. M. C. Public Health; 9: 484.
26. Marra, F. and Bertolani, C. (2009): Adipokines in liver diseases. Hepatology; 50 (3): 957-969.
27. McCarthy T. C.; Zuniga L. A.; Zabel B. A.; Butcher E. C. and Sinal C. J. (2008): The novel adipokine chemerin significantly increases cholesterol uptake in human macrophages. Fed. Am. Soci. Exp. Biol. J.; 22: 948. 8.
28. McGowan M. W.; Artiss J. D. and Strodbrgh D. R. (1983): A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin. Chem.; 29: 273-278.
29. National Cholesterol Education Program (2002): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation; 106: 3143-3421.
30. Olufadi R and Byrne CD. (2008): Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol. Jun 2008; 61 (6): 697-706.
31. Ouchi, N., Parker, J. L., Lugus, J. J. and Walsh, K. (2011): "Adipokines in inflammation and metabolic disease, " Nature Reviews Immunology; 11 (2): 85-97
32. Parlee, D S; Ernst, M C; Muruganandan, S; Sinal C J and Goralski, K B (2010): Serum Chemerin Levels Vary with Time of Day and Are Modified by Obesity and Tumor Necrosis Factor-{alpha}. Endocrin 151 (6): 2590-2602.
33. Sell H.; Laurencikiene J.; Taube A.; Eckardt K.; Cramer A.; Horrighs A.; Arner P. and Eckel J. (2009): Chemerin Is a Novel Adipocyte-Derived Factor Inducing Insulin Resistance in Primary Human Skeletal Muscle Cells. Diabetes; 58 (12): 2731-2740.
34. Shin HY, Lee DC, Chu SH, Jeon JY, Lee MK, Im JA, Lee JW. (2011): Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin Endocrinol; Accepted 2011 Sep 2. (http: //www. ncbi. nlm. nih. gov/pubmed)
35. Shirai K. (2004): Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr. Med. Res. Opin.; 20 (3): 295-304.
36. Stejskal D.; Karpisek M.; Hanulova Z. and Svestak M. (2008): Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomed. Pap.; 152 (2): 217-221.
37. Suzuki A.; Kosuge K.; Nanyu O.; Watanabe H.; Watanabe T.; Usuda Y.; Sasaki S. and Aizawa Y. (2010): Five Year Study of Cardiovascular Risk Factors in Japanese People: Implications Concerning New Onset of Metabolic Syndrome. Inter. Med.; 49: 1-6.
38. Takahashi M, Okimura Y, Iguchi G, Nishizawa H, Yamamoto M, Suda K, Kitazawa R, Fujimoto W, Takahashi K (2011): Chemerin regulates β-cell function in mice. Sci Rep.; 1: 123.
39. Takahashi M.; Takahashi Y.; Takahashi K.; Zolotaryov F. N.; Hong K. S.; Kitazawa R.; Iida K.; Okimura Y. (2008): Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett.; 582 (5): 573-578.
40. Tan, B K; Chen, J; Farhatullah, S; Adya, R; Kaur, J; Heutling, D; Lewandowski, K C; O'Hare, J P; Lehnert, H and Randeva, H S (2009): Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes, 58 (9) 1971-1977.
41. Wang L. Y.; Wei L.; Yu H. Y.; Zhang Y. and Jia W. P. (2009): Relationship of serum chemerin to obesity and type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi.; 89 (4): 235-238.
42. Warnick G. R.; Knopp R. H. and Fitzpatrick V. (1990): Estimating low density lipoprotein cholesterol by the friedwald equation is adequate for classifying patients on the basis of nationally recommended cut points. Clin. Chem.; 36: 15-17.
43. Wolfs M. G. M.; Hofker M. H.; Wijmenga C. and van Haeften T. W. (2009): Type 2 Diabetes Mellitus: New Genetic Insights will lead to New Therapeutics. Curr. Genomics; 10 (2): 110-118.
44. Yamawaki H. (2011): Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull.; 34 (3): 307-10.
45. Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G. (2012): The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine; 41 (2): 281-8.
46. Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, Boden G, Li L (2010): Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med.; 58 (7): 883-6.
47. Yoo HJ, Choi HY, Yang SJ, Kim HY, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH. (2012): Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb.; 19 (1): 59-66; discussion 67-8.
48. Zeyda M. and Stulnig T. M. (2009): Obesity, Inflammation and Insulin Resistance-A Mini Review. Gerontology; 55: 379-386.